Myriad Genetics, Inc. (MYGN) has a market capitalization of $459.13M and trades at $4.91. The 52-week range is 3.76-8.63.
Key metrics include a trailing Price-to-Earnings (P/E) ratio of -1.2, Earnings Per Share (EPS) of $-3.96, annual revenue of $824.5M.
The stock has a beta of 1.64, operates in the Healthcare sector.
